In the wake of a high-profile federal court ruling casting doubt on the definition of eligible “patient” in the 340B [...] …
HRSA released a new web page with resources on the agency's 340B program patient definition and compliance guidelines.
Month: December 2023
The White House plans to release a revised administrative dispute resolution process for the 340B program this month.
The federal 340B program remains on track to publish a final rule this month revising its administrative dispute resolution (ADR) [...] …
The Minnesota Department of Health finalized guidance for the state's new annual 340B covered entity reporting requirements.
Stakeholder comments are due Tuesday on Minnesota’s recently published guidance to implement one of the nation’s first state laws requiring [...] …
The Michigan Department of Health and Human Services released a new 340B hospital billing and reporting rule.
At the start of 2024, Michigan 340B hospitals can bill the state at higher payment rates for outpatient drugs; later [...] …
Novo Nordisk will issue 340B provider refunds for formulations of two hemophilia drugs, according to a HRSA manufacturer notice.
Novo Nordisk will issue its fifth round of refunds this year on prices charged to 340B providers. The latest are [...] …
A sweeping healthcare package with 340B reporting provisions from Rep. Cathy McMorris Rodgers (R-Wash.) was passed by the House of Representatives.
The U.S. House of Representatives last night passed a sweeping healthcare package that would require 340B providers to publicly report [...] …
Maureen Testoni, president and CEO of 340B Health, said she anticipates bipartisan legislation on drugmaker 340B contract pharmacy restrictions.
Months after it was expected, bipartisan legislation to prevent drugmaker restrictions on the use of contract pharmacies by 340B providers [...] …
The Missouri state senate recently passed a 340B contract pharmacy access bill.
A Missouri state senator has filed to reintroduce a bill that would bar drugmaker 340B contract pharmacy restrictions and pharmacy [...] …
Wisconsin lawmakers have introduced bills in both legislative chambers that would bar PBMs from differentially reimbursing providers on the basis of their 340B status.
Just a week after Wisconsin state senators introduced a bipartisan bill to bar disparate treatment of 340B providers by pharmacy [...] …
Jean-Jacques Bienaime, CEO of drugmaker BioMarin, discussed the impact of 340B on pharmaceutical sales during an investor earnings call.
Pharmaceutical company executives discussed a range of 340B-related developments in recent third quarter investor calls. An executive for BioMarin Pharmaceutical, [...] …
